Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by O. Al Tabaa
SAT0199 Switch From Innovator Etanercept to Biosimilar Etanercept in Inflammatory Rheumatic Diseases: The Experience of Cochin University Hospital Paris-France.
Related publications
Observational Study of Inflammatory Arthritis Treatment by Etanercept Originator Switched to an Etanercept Biosimilar
Reumatologia
Rheumatology
Allergy
Immunology
GP2015: An Etanercept Biosimilar
BioDrugs
Medicine
Biotechnology
Pharmacology
Switch From Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients With Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results From the Phase III, Randomized, Double-Blind EQUIRA Study
Arthritis Research & Therapy
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
Rheumatology and Therapy
Evaluation of the Cost Saving Potential of Introducing an Etanercept Biosimilar (Benepali®) for the Treatment of All Licensed Adult Etanercept Indications in the UK
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Response To: Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
Journal of Immunology Research
Medicine
Allergy
Immunology
Modulation of Inflammatory Gene Transcripts in Psoriasis Vulgaris: Differences Between Ustekinumab and Etanercept
Journal of Allergy and Clinical Immunology
Allergy
Immunology
THU0218 the Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results From the Turkbio Registry
Pharmacogenetics of Etanercept in Rheumatoid Arthritis
Pharmacogenomics
Molecular Medicine
Genetics
Pharmacology
